Endo Health Solutions Inc (ENDP): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Endo Health Solutions ( ENDP) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.8%. By the end of trading, Endo Health Solutions rose $0.57 (1.6%) to $35.45 on average volume. Throughout the day, 3,502,198 shares of Endo Health Solutions exchanged hands as compared to its average daily volume of 2,583,800 shares. The stock ranged in a price between $33.94-$36.69 after having opened the day at $33.94 as compared to the previous trading day's close of $34.88. Other companies within the Drugs industry that increased today were: Celsion Corporation ( CLSN), up 39.5%, Aegerion Pharmaceuticals ( AEGR), up 14.1%, Vermillion ( VRML), up 10.1% and Biocryst Pharmaceuticals ( BCRX), up 10.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo Health Solutions has a market cap of $3.8 billion and is part of the health care sector. Shares are up 29.2% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Endo Health Solutions a buy, 4 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Endo Health Solutions as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, disappointing return on equity and weak operating cash flow.

On the negative front, Biota Pharmaceuticals ( BOTA), down 66.8%, ARCA biopharma ( ABIO), down 13.2%, Senesco Technologies ( SNT), down 11.4% and Senesco Technologies ( SNTI), down 11.4% , were all laggards within the drugs industry with Pfizer ( PFE) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

3 Biotech Stocks on Readers' Minds